<u></u>	Application No.	Applicant(s)
	дрисацоп но.	
Notice of Allowability	10/642,933	LOUWET ET AL.
	Examiner	Art Unit
	Camie S. Thompson	1774
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>Amendment filed 5/08/06</u> .		
2. ☑ The allowed claim(s) is/are <u>1-48</u> .		
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5 Notice of Informal B	otent Application (PTO 152)
 Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) 	6. ☐ Interview Summary	atent Application (PTO-152)
2. Notice of Draitpersoft's Faterit Drawing Neview (F10-940)	Paper No./Mail Dat 08), 7. ☐ Examiner's Amendn	
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 	08), 7. ☐ Examiner's Amenda	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	

Application/Control Number: 10/642,933

Art Unit: 1774

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: The prior art does not provide for the recited layer configuration on a support wherein the layer configuration contains an optionally substituted 3,4-alkylenedioxythiophene structural units, in which the two alkoxy groups may be the same or different or together represent an optionally substituted oxy-alylene-oxy bridge, and a compound selected from the group consisting polyphosphoric acids, polyphosphoric acid salts, thia-alkanedicarboxylic acids, cyclohexadiene compounds and polyhydroxy compounds selected from the group consisting of tetronic acid derivatives; odihydroxybenzene compounds with at least one sulpho group, compounds according to the formula (1)

wherein R¹ and R² are independently H, -OH or alkyl, and n and m are independently 1, 2 or 3; compounds according to formula (II)

wherein p and q are independently 2, 3 or; compounds hydrolysable to tetronic acid derivatives; compounds hydrolysable to compounds according to formula (I); and sulpho-substituted 2-thia-alkyl-benzimidazole. Additionally, the prior art does not provide for a light emitting diode, photovoltaic device, solar cell, transistor and electroluminescent device comprising the recited layer configuration.

Application/Control Number: 10/642,933 Page 3

Art Unit: 1774

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communication from the examiner should be directed to Camie S. Thompson whose telephone number is (571) 272-1530. The examiner can normally be reached on Monday through Friday from 7:30 am to 4:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Rena L Dye, can be reached at (571) 272-3186. The fax phone number for the Group is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

DAWN GARRETT PRIMARY EXAMINER